Cullinan Oncology Inc logo

CGEM

Cullinan Oncology Inc

$13.07

Earnings Summary

Revenue
$0Mn
Net Profits
$-12.1Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Cullinan Oncology Inc’s revenue fell -100% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Cullinan Oncology Inc has generated 100% jump in its revenue since last 3-months.

Net Profits:

Cullinan Oncology Inc’s net profit fell -17182.86% since last year same period to $-12.1Mn in the Q1 2022. On a quarterly growth basis, Cullinan Oncology Inc has generated -136.67% fall in its net profits since last 3-months.

Net Profit Margins:

Cullinan Oncology Inc’s net profit margin fell -Inf% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Cullinan Oncology Inc has generated -Inf% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Cullinan Oncology Inc post its latest quarter earnings

EPS Estimate Current Quarter
5.42
EPS Estimate Current Year
5.42

Highlights

EPS Estimate Current Quarter:

Cullinan Oncology Inc’s earning per share (EPS) estimates for the current quarter stand at 5.42 - a 988.52% jump from last quarter’s estimates.

EPS Estimate Current Year:

Cullinan Oncology Inc’s earning per share (EPS) estimates for the current year stand at 5.42.

Key Ratios

Key ratios of the Cullinan Oncology Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.27
Return on Assets (ROA)
-0.13
Return on Equity (ROE)
0.2
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Cullinan Oncology Inc’s earning per share (EPS) fell -15782.35% since last year same period to -0.27 in the Q1 2022. This indicates that the Cullinan Oncology Inc has generated -15782.35% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Cullinan Oncology Inc’s return on assets (ROA) stands at -0.13.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Cullinan Oncology Inc’s return on equity (ROE) stands at 0.2.

Dividend Per Share (DPS):

Cullinan Oncology Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-16
-0.61
-0.27
55.74%

Company Information

Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.

Organisation
Cullinan Oncology Inc
Headquarters
One Main Street, Cambridge, MA, United States, 02142
Employees
24
Industry
Other Consumer Services